352 related articles for article (PubMed ID: 19840566)
21. Comparison of patient outcomes with bivalirudin versus unfractionated heparin in percutaneous coronary intervention.
Watson K; Seybert AL; Saul MI; Lee JS; Kane-Gill SL
Pharmacotherapy; 2007 May; 27(5):647-56. PubMed ID: 17461699
[TBL] [Abstract][Full Text] [Related]
22. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
White HD; Chew DP; Hoekstra JW; Miller CD; Pollack CV; Feit F; Lincoff AM; Bertrand M; Pocock S; Ware J; Ohman EM; Mehran R; Stone GW
J Am Coll Cardiol; 2008 May; 51(18):1734-41. PubMed ID: 18452778
[TBL] [Abstract][Full Text] [Related]
24. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
25. Comparison of heparin and bivalirudin in patients undergoing percutaneous coronary intervention without use of glycoprotein IIb/IIIa inhibitors.
Abtahian F; Waldo S; Jang IK
Catheter Cardiovasc Interv; 2015 Sep; 86(3):390-6. PubMed ID: 25753749
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial).
Goto K; Lansky AJ; Ng VG; Pietras C; Nargileci E; Mehran R; Parise H; Feit F; Ohman EM; White HD; Bertrand ME; Desmet W; Hamon M; Stone GW
Am J Cardiol; 2014 Dec; 114(11):1638-45. PubMed ID: 25312637
[TBL] [Abstract][Full Text] [Related]
28. Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in "Real World" practice.
Showkathali R; Davies JR; Parker M; Taggu W; Tang KH; Clesham GJ; Gamma RA; Sayer JW; Aggarwal RK; Kelly PA
Cardiovasc Revasc Med; 2013; 14(5):289-93. PubMed ID: 23972537
[TBL] [Abstract][Full Text] [Related]
29. The safety and effectiveness of bivalirudin in female patients with acute myocardial infarction undergoing primary angioplasty: A subgroup analysis of the BRIGHT trial.
Liang Z; Li Y; Wang J; Wang D; Wang S; Ma L; Liu H; Yang L; Stone GW; Han Y
Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():608-15. PubMed ID: 26762481
[TBL] [Abstract][Full Text] [Related]
30. Efficiency and safety of bivalirudin in patients undergoing emergency percutaneous coronary intervention via radial access: A subgroup analysis from the bivalirudin in acute myocardial infarction versus heparin and GPI plus heparin trial.
Wang H; Li Y; Cong H; Ding S; Liu B; Li L; Chen Y; Jia S; Jing Q; Zhao X; Liu H; Liang Z; Li J; Bao D; Han Y
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1157-1165. PubMed ID: 27677411
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
[TBL] [Abstract][Full Text] [Related]
32. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
33. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.
Cortese B; Micheli A; Picchi A; Bandinelli L; Brizi MG; Severi S; Limbruno U
Coron Artery Dis; 2009 Aug; 20(5):348-53. PubMed ID: 19543084
[TBL] [Abstract][Full Text] [Related]
35. Bivalirudin for patients with acute coronary syndromes.
Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
[TBL] [Abstract][Full Text] [Related]
36. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
Kastrati A; Neumann FJ; Schulz S; Massberg S; Byrne RA; Ferenc M; Laugwitz KL; Pache J; Ott I; Hausleiter J; Seyfarth M; Gick M; Antoniucci D; Schömig A; Berger PB; Mehilli J;
N Engl J Med; 2011 Nov; 365(21):1980-9. PubMed ID: 22077909
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Feit F; Manoukian SV; Ebrahimi R; Pollack CV; Ohman EM; Attubato MJ; Mehran R; Stone GW
J Am Coll Cardiol; 2008 Apr; 51(17):1645-52. PubMed ID: 18436116
[TBL] [Abstract][Full Text] [Related]
39. Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty.
Bonello L; de Labriolle A; Roy P; Steinberg DH; Pinto Slottow TL; Xue Z; Kaneshige K; Torguson R; Suddath WO; Satler LF; Kent KM; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2009; 10(3):156-61. PubMed ID: 19595396
[TBL] [Abstract][Full Text] [Related]
40. Temporal trends, safety, and efficacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium.
Gurm HS; Smith DE; Chetcuti SJ; Share D; Khanal S; Riba A; Carter AJ; Lalonde T; Kline-Rogers E; O'Donnell M; O'Neill W; Safian R; Moscucci M;
J Interv Cardiol; 2007 Jun; 20(3):197-203. PubMed ID: 17524111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]